Below is an overview of various sections of The Swedish COVID-19 & Pandemic Preparedness Portal where information about research data and resources relevant to COVID-19 can be found. For a short background on this topic below, see the description below.
Data highlights (33)

Large scale immunofluorescence to explore the host cell response to SARS-CoV-2 infection
2022-04-25
Expression of 602 host proteins were evaluated in populations of infected and non-infected cells using immunofluorescence. ≈75,000 images have been published as a resource for further studies.
Read more

Direct RT-PCR used to monitor Omicron BA.1/BA.2 variant transition in Sweden
2022-04-04
Lentini and collegues used direct RT-PCR to show the transition from Omicron BA.1 to sub-variant BA.2 in Sweden Jan-March 2022. New Preprint from Reinius lab which shares data and code.
Read more

Interactions between fragments and SARS-CoV-2 nsp10 provide insight into the viral replications
2022-03-01
Interactions between fragments and SARS-CoV-2 nsp10 have been successfully identified and characterised by Kozielski and colleagues. Data shared on the Protein Data Bank and Zenodo.
Read more
Dashboards (6)
Sample collections (35)
Name | Type | Size | Materials |
---|---|---|---|
Dalarna biobank (forskningsprov och nyinsamlade prov):SARS-CoV-2 PCR positiva Dalarna |
Healthcare sample collection | 1000 - 10.000 | Nasal swab Throat swab |
Gävleborg biobank:Klinisk mikrobiologi |
Healthcare sample collection | 1000 - 10.000 | Nasal swab Serum Throat swab Other |
Halland biobank:Patologen Halland |
Healthcare sample collection | 100 - 1000 | Tissue (stained sections/slides) Tissue (paraffin preserved) |
Ongoing research projects (117)
Project title | Funder | Topics |
---|---|---|
The COMMUNITY Study - COVID-19 Biomarker and Immunity StudyHost institute: Karolinska Institute / Danderyd Hospital |
SciLifeLab / Knut and Alice Wallenberg Foundation | COVID-19Infectious diseases |
Validation and characterisation of novel plasma biomarkers for risk prediction and stratification of COVID-19 patientsHost institute: KTH Royal Institute of Technology |
SciLifeLab / Knut and Alice Wallenberg Foundation | COVID-19Infectious diseases |
NEVERMORE COVID – Establishing a drug discovery platform for corona virus diseaseHost institute: Uppsala University |
SciLifeLab / Knut and Alice Wallenberg Foundation | COVID-19Infectious diseases |
Open funding opportunities (2)
Call title | Deadline | Funder | Topics |
---|---|---|---|
The purpose of the project grant is to give researchers the freedom to formulate by themselves the research concept, method and implementation, and to solve a specific research task within a …
|
August 17, 2022 | Swedish Research Council | COVID-19Infectious diseasesAntibiotic resistance |
Projects in this call can address the medium to long-term effects for individuals and groups, for Nordic societies, and for the Nordic community, of the COVID-19 pandemic within the thematic …
|
June 8, 2022 | NordForsk | COVID-19 |
Background
Coronavirus disease (COVID-19) is an infectious disease caused by the novel SARS-CoV-2 virus. Since its start in early 2020, the COVID-19 pandemic has challenged societies worldwide. While most people infected experience mild to moderate respiratory illness and recover without treatment, the disease can be severe or fatal. Advanced age and underlying medical conditions, such as cardiovascular disease, diabetes, cancer, or chronic respiratory disease, have all been associated with increased risk of severe outcome. However, anyone independent of age or comorbidities is at risk for COVID-19 severe disease outcome. As of March 2022, more than 200 million confirmed cases and over 4 million deaths have been reported.
The research community worldwide has, in an unprecedented way, focused their research efforts towards investigating the novel SARS-CoV-2 virus and variants, as well as variants of concern (VoCs) have emerged more, and the impact of COVID-19 on human body. These contributions from the research community have been a crucial part of the rapid vaccine development. Vaccines are today the cornerstone of global pandemic management. Whilst vaccines were rolled out in record time and have proven very effective diminishing the risk of severe COVID-19 disease and death, many research questions remain. Although we are now entering a more endemic period, COVID-19 is a serious health threat worldwide. Research and lessons learned are crucial for early detection of outbreaks, ability to rapidly identify potential new SARS CoV-2 variants of concern, development of additional treatment options, and future pandemic preparedness. There is still an uncertainty regarding the duration of vaccine protection and effectiveness of booster doses. In addition, vaccine escape has been shown by several current VoCs which could make vaccines less efficient.